December 8, 2017 06:44 AM ESTUpdated 06:57 AM
Financing

De­nali IPO hits a 2017 record $1.7B mar­ket val­u­a­tion, rais­ing $250M for neu­rode­gen­er­a­tion R&D

John Carroll

Editor & Founder

De­nali Ther­a­peu­tics’ team plans to break through a lot of bar­ri­ers in biotech — most no­tably look­ing to de­vel­op a drug for Alzheimer’s that ac­tu­al­ly works …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times